Health Highlights: March 6, 2017

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:

New Drug Reduces Nighttime Urination

The first drug to reduce the number of times adults have to urinate during the night has been approved by the U.S. Food and Drug Administration.

Noctiva is a nasal spray for adults who make at least two nighttime trips to the bathroom due to causes such as certain medications, chronic heart failure, poorly controlled diabetes, and bladder and prostate problems, the Associated Press reported.

The spray, used about 30 minutes before bedtime each night, helps the kidneys absorb more water in order to reduce the amount of urine.

Noctiva carries a black box warning — the FDA’s strongest — about the risk of dangerously low levels of sodium in the blood. Other possible side effects include colds, bronchitis, a rise in blood pressure, dizziness, back pain and nose bleeds, the AP reported.

The drug was developed by Serenity Pharmaceuticals LLC and Allergan PLC.


Liver Transplant Groundbreaker Dies

Groundbreaking liver transplant surgeon Dr. Thomas Starzl has died at age 90.

Starzl died Saturday at his home in Pittsburgh, the University of Pittsburgh announced on behalf of the doctor’s family, the Associated Press reported.

In 1963, Starzl performed the world’s first attempted liver transplant, and in 1967 he performed the world’s first successful liver transplant in 1967. He was also a trailblazer kidney transplantation from cadavers.

Starzl was also a leading researcher in the field of anti-rejection drugs.

“We regard him as the father of transplantation,” said Dr. Abhinav Humar, clinical director of the Thomas E. Starzl Transplantation Institute, the AP reported. “His legacy in transplantation is hard to put into words — it’s really immense.”

Leave a Reply